CanariaBio Inc Announces Enrollment Completion of randomized Phase 2 study of Oregovomab in combination with chemotherapy as neo-adjuvant treatment of patients with Advanced Ovarian Cancer
SEOUL,South Korea,Aug. 23,2024-- CanariaBio Inc,a leading late-stage biotechnology company,announces the successful completion of enrollment of 88 patients in a randomized Phase 2 study of oregovomab